The IBD SmartSelect Composite Rating for ANI Pharmaceuticals rose from 92 to 97 Monday.
Looking For The Best Stocks To Buy And Watch? Start Here
The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
ANI Pharmaceuticals is currently extended beyond a proper buy zone after breaking out from a 77.00 buy point in a cup without handle.
The stock sports an 89 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 89% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 76% earnings gain for Q2. Revenue growth increased 53%, up from 43% in the prior quarter. That marks one quarter of rising revenue growth.
ANI Pharmaceuticals holds the No. 1 rank among its peers in the Medical-Generic Drugs industry group. Collegium Pharmaceutical and Dr. Reddy's Labs ADR are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
